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Alzheimer’s disease (AD) is the most common neurodegenerative disorder and the primary form of dementia in the elderly.
Polymorphisms of genes involved in folate metabolism have been frequently suggested as risk factors for sporadic AD. A common
c.80G>A polymorphism (rs1051266) in the gene coding for the reduced folate carrier (SLC19A1 gene, commonly known as RFC-1
gene) was investigated as AD risk factor in Asian populations, yielding conflicting results. We screened a Caucasian population
of Italian origin composed of 192 sporadic AD patients and 186 healthy matched controls, for the presence of the RFC-1 c.80G>A
polymorphism, and searched for correlation with circulating levels of folate, homocysteine, and vitamin B12. No difference in
the distribution of allele and genotype frequencies was observed between AD patients and controls. No correlation was observed
among the genotypes generated by the RFC-1 c.80G>A polymorphism and circulating levels of folate, homocysteine, and vitamin
B12 either in the whole cohort of subjects or after stratification into clinical subtypes. Present results do not support a role for the
RFC-1 c.80G>A polymorphism as independent risk factor for sporadic AD in Italian Caucasians.
1. Introduction
Alzheimer’s disease (AD) is the most common neurodegen-
erative disorder and the primary form of dementia in the
elderly, clinically characterized by a progressive neurodegen-
eration in selected brain regions, including the temporal and
parietal lobes and restricted regions within the frontal cortex
and the cingulate gyrus [1]. The term “dementia” describes
a set of symptoms, which include loss of memory, mood
changes, and problems with communication and reasoning.
Indeed, AD leads to memory loss accompanied by changes
of behaviour and personality severe enough to affect daily
life. The disease symptoms get worse over time and available
treatments may only help in keeping patients from getting
worse for a limited period. It is estimated that there are over
36 million people living with dementia in the world, and
projections estimate that the number of affected individuals
will increase quickly in the next decades following the world-
wide increase in life expectancy.Therefore, there is particular
interest in searching for early detectable biomarkers allowing
us to better characterize those individuals at increased risk to
develop AD [1].
Homocysteine (hcy), folates, and related B-vitamins par-
ticipate in one-carbon metabolism, a pathway required for
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Table 1: Demographic characteristics of the study population and data on plasma total homocysteine and serum folate and vitamin B12 levels.







AD 192 65 (33.8%) 127 (66.2%) 76.4 ± 7.3 21.2 ± 1.7 7.1 ± 0.8b 407.8 ± 25.2
Controls 186 72 (38.7%) 114 (61.3%) 73.5 ± 6.4 14.6 ± 0.7 8.2 ± 1.0 437.9 ± 30.9
aAvailable from 104AD and 64 controls.
bSignificant difference versus controls (𝑃 value obtained with analysis of covariance using log transformed data and corrected for age and gender).
DNA synthesis and methylation reactions [2]. Both prospec-
tive and retrospective studies suggest that impairments of
one-carbonmetabolism leading to increased hcy levels might
contribute to Alzheimer’s disease (AD), and genetic poly-
morphisms of metabolic enzymes have been suspected to
contribute to those impairments as well as to sporadic AD
risk [2–16].
The reduced folate carrier (RFC-1) participates in the
uptake of folate cofactors from the blood [17], and a common
c.80G>A polymorphism (rs1051266) in the gene coding
for RFC-1 (SLC19A1 gene: solute carrier family 19 member
1, commonly known as RFC-1 gene) was hypothesized to
have a functional role in folate transport [18]. Subsequent
studies gave conflicting results, and the contribution of
this polymorphism to circulating folate or hcy levels is still
a matter of debate [15, 19–21]. In 2009, Bi and coworkers
observed association of both the RFC-1 80G allele and the
GG genotype with increased risk of late-onset AD in Han
Chinese individuals [15]. However, no significant effect of
the RFC-1 80G>A polymorphism on plasma folate and hcy
levels was detected [15]. A more recent study performed in
Indian subjects failed to find association of the RFC-1 80G>A
polymorphism with risk of AD or vascular dementia, and no
association of the polymorphismwith serum folate levels was
detected [21]. Moreover, others failed to observe association
of rs1051266 with cognitive status, folate, and hcy levels in
Caucasian Parkinson’s disease (PD) patients [22].
At best of our knowledge, except for the above two con-
flicting studies in Asian populations [15, 21], there is no other
available case-control genetic association study evaluating the
possible contribution of rs1051266 to AD risk. Therefore, we
performed the present pilot study to address the contribution
of the RFC-1 80G>A polymorphism to AD risk in a cohort
of Caucasian sporadic AD patients and healthy matched
controls and searched for correlation between rs1051266 and
circulating levels of folate, hcy, and vitamin B12.
2. Materials and Methods
2.1. Study Population. DNA samples from 192 sporadic AD
patients and 186 matched controls were collected at the
Department of Neurosciences, University of Pisa, and at the
Department of Neuroscience, Psychology, Drug Research
and Child Health, University of Florence (Table 1). The AD
patients were clinically evaluated according to the published
guidelines and the AD diagnosis fulfilled the Diagnostic
and Statistical Manual of Mental Disorders criteria (DSM-
IV) [23, 24]. According to disease age at onset and absence
of a family history of dementia all the AD subjects were
assumed to be sporadic late-onset (>65 years) cases. The
apolipoprotein E (APOE) genotype was known for 30 AD
patients and 40 controls, and APOE 𝜀4 (+) carriers were
higher in AD patients than in controls (47% versus 27%).
As normal controls we recruited healthy volunteer subjects
without relationship with the AD patients. Controls were
selected among people ageingmore than 65 years (i.e., people
at risk to develop late onset AD) and were matched to AD
patients for age (±3 years) and gender (Table 1), as well
as for ethnicity and geographic origin (all individuals were
Caucasians from northern Tuscany and neighbouring areas).
Family history of dementia was ascertained, excluding all the
subjects with even one relative who developed AD or other
dementias. All the control subjects were evaluated in order to
exclude the presence of cognitive impairment (MMSE score
over 26). Each subject gave an informed and written consent
for genotype analysis.The studywas performed in accordance
with the Declaration of Helsinki and approved by the Ethics
Committee of the Pisa University Hospital (Protocol number
3618/2012).
2.2. Genotyping. Genomic DNA was isolated from whole
blood by means of the QIAamp Blood Mini Kit (Qiagen,
Milan, Italy) following the manufacturer’s instructions. The
genotyping protocol for the RFC-1 80G>A polymorphism
was adapted from Bi et al. [15]: a 230-bp product was
amplified using 1.25 units of Taq DNA polymerase (Invit-
rogen, Milan, Italy), 10 pmol of the forward primer (5󸀠-
AGCGTCACCTTCGTCCC-3󸀠) and the reverse primer (5󸀠-
TCCCGCGTGAAGTTCTTG-3󸀠), 0.15mM of each dNTP,
1.5mMMgCl
2
, and 30 ng of genomic DNA in a total volume
of 25 𝜇L. PCR conditions consisted of an initial denaturation
step of 5 minutes at 95∘C, followed by 40 cycles of 30 s at
95∘C, 45 s at 62∘C, and 45 s at 72∘C and a final extension of 10
minutes at 72∘C. The PCR products were digested with Cfo I
(SIGMA,Milan, Italy) and resulted in three fragments of 125-
bp, 68-bp, and 37-bp in the presence of the 80G allele, while
the 80A allele produced two fragments of 162- and 68-bp.
Digestion products were visualized after electrophoresis on a
3% agarose gel containing ethidiumbromide. Internal control
samples, whose genotypes had been previously assessed, were
always included and analyzed on each gel.
2.3. Biochemical Analyses. Peripheral blood samples for the
evaluation of folate, total homocysteine (t-hcy), and vitamin
B12 levels were collected from 104 AD patients and 64
healthy controls. Plasma was immediately separated and
stored in freezer at −80∘C. All the analyses were performed
with standard protocols at the diagnostic laboratory of
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Table 2: Distribution of genotypes and allele frequencies of the RFC-1 80G>A polymorphism in Alzheimer’s disease and control individuals.
Genotypes/alleles AD patients
𝑛 = 192 (%)
Controls
𝑛 = 186 (%) Crude OR (95% CI) 𝑃 value
Adjusted ORa
(95% CI) 𝑃 value
Genotypes
GG 53 (27.6) 49 (26.3) 1.00b — 1.00b —
GA 102 (53.1) 98 (52.7) 0.96 (0.59–1.55) 0.87 0.97 (0.58–1.62) 0.89
AA 37 (19.3) 39 (21.0) 0.88 (0.48–1.59) 0.66 0.94 (0.50–1.78) 0.86
AA + GA versus GG 139 (72.4) 137 (73.7) 0.94 (0.60–1.48) 0.78 0.96 (0.59–1.57) 0.89
Alleles
Allele G 0.54 0.53 1.00b — —
Allele A 0.46 0.47 0.94 (0.71–1.25) 0.69 0.98 (0.72–1.32) 0.88
aAdjusted for age and gender.
bReference value for OR.
the University Hospital of Pisa, as previously described by
us [5]. In order to minimize the effect of polymedication
in our cohort of subjects, individuals taking medicaments
or supplements known or suspected to interfere with one-
carbon metabolism were not enrolled for the study.
2.4. Statistical Analyses. To verify that allele frequencies were
in Hardy-Weinberg equilibrium and to assess differences
in allele distributions between groups, we used the Chi-
square (𝜒2) analysis. The differences in genotype frequen-
cies were analyzed by 2 × 2 contingency tables using 𝜒2
analysis. Logistic regression analyses were used to examine
the associations between the study polymorphism and AD
risk by estimating odds ratios (ORs) and 95% confidence
intervals (CIs) with and without adjustment for age and
gender. All individual values were analyzedwith theMedCalc
12.5 statistical package for Windows. The statistical package
QUANTO 1.2.4.exe was used to evaluate the statistical power
of the study. Given a case-control cohort of almost 190
subjects each and a minor allele frequency ranging from
0.45 to 0.49 from present and previous studies in Caucasians
[25, 26], the study had 80% power to detect ORs of 1.5 or
higher under the additive model.
Analysis of covariance (ANCOVA) was used to evaluate
differences in mean plasma t-hcy, folate, and vitamin B12
levels among groups, including age at sampling and gender as
covariates. ANCOVA was also used to correlate biochemical
data with the possible genotypes generated by the studied
polymorphism, including age and gender as covariates. Since
data on t-hcy, folates, and vitamin B12 had a skewed distribu-
tion, logarithm transformation of all values was done before
analysis. Analyses were performed with the Statgraphics
Centurion XVI.1 software package for Windows.
3. Results
3.1. RFC-1 Allele and Genotype Frequencies among Groups.
Table 2 shows the distribution of RFC-1 80G>A genotype
and allele frequencies in AD patients and controls. Geno-
type distributions in controls conformed to Hardy-Weinberg
expectations (𝑃 = 0.44). The frequencies of the RFC-1
80A minor allele in AD patients and controls were 0.46
and 0.47, respectively (𝑃 = 0.69). Also the distribution
of genotype frequencies was similar and not significantly
different betweenAD and control subjects (Table 2). As stated
in the Materials and Methods section the APOE genotype
was known only for a small subgroup of AD and control
individuals. However, no significant difference in RFC-1
80G>A allele frequencies was observed between APOE 𝜀4
(+) AD patients and APOE 𝜀4 (+) controls (𝑃 = 0.37. Not
shown).
3.2. Folate, t-hcy, and Vitamin B12 Levels among Groups.
Data on circulating t-hcy, folate, and vitamin B12 levels were
available from 104 AD and 64 control individuals (Table 1).
Analysis of variance revealed that mean t-hcy levels were
higher in AD patients than in controls (𝑃 = 0.002), but
after inclusion of age at sampling and gender as covariates in
the analysis the difference between AD and control subjects
was not statistically significant (𝑃 = 0.14), whilst a strong
effect of age at sampling on increasing t-hcy levels was
observed (𝑃 < 0.001). A significant difference was observed
concerning serum folate levels between AD and control
subjects (𝑃 = 0.01) that remained significant after correcting
for age at sampling and gender (𝑃 = 0.04). Also increasing
age at sampling showed a significant contribution to reducing
serum folate levels in our population (𝑃 = 0.03). No
difference in mean vitamin B12 levels was observed between
AD and controls (𝑃 = 0.31 without correction and 𝑃 = 0.47
after correction for age and gender). No significant effect of
age and gender on mean vitamin B12 levels was observed.
3.3. Correlation between RFC-1 Genotypes and Biochemical
Data. Table 3 shows the correlation between RFC-1 80 (GG,
GA, AA, and GA+AA) genotypes and circulating levels of
t-hcy, folate, and vitamin B12. Analyses were performed in
the whole cohort of subjects (AD + controls) and in AD and
control individuals separately. No significant difference was
observed for each of the studied biochemical markers among
different RFC-1 genotypes (Table 3).
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Table 3: Correlation between RFC-1 80G>A genotypes and biochemical data.
RFC-1 GG RFC-1 GA RFC-1 AA RFC-1 GA + AA 𝑃 valuea
Total (𝑛 = 168) 39 95 34 129
Folate (ng/mL, mean ± SEM) 8.4 ± 1.2 7.9 ± 0.8 5.8 ± 1.3 7.3 ± 0.7 0.51
t-hcy (𝜇mol/L, mean ± SEM) 15.6 ± 2.2 19.2 ± 1.4 19.1 ± 2.2 19.1 ± 1.2 0.55
Vit. B12 (pg/mL, mean ± SEM) 462.1 ± 39.3 421.7 ± 24.9 366.1 ± 41.6 406.9 ± 21.4 0.63
AD (𝑛 = 104) 26 60 18 78
Folate (ng/mL, mean ± SEM) 8.1 ± 1.5 7.4 ± 1.0 4.9 ± 1.8 6.8 ± 0.9 0.65
t-hcy (𝜇mol/L, mean ± SEM) 16.1 ± 3.5 22.6 ± 2.2 22.1 ± 4.1 22.5 ± 2.0 0.50
Vit. B12 (pg/mL, mean ± SEM) 467.4 ± 47.9 398.7 ± 31.6 351.7 ± 57.5 387.7 ± 27.6 0.70
Controls (𝑛 = 64) 13 35 16 51
Folate (ng/mL, mean ± SEM) 8.3 ± 2.2 8.5 ± 1.3 7.1 ± 1.9 8.1 ± 1.1 0.75
t-hcy (𝜇mol/L, mean ± SEM) 13.2 ± 1.4 14.3 ± 0.8 16.6 ± 1.2 15.0 ± 0.7 0.17
Vit. B12 (pg/mL, mean ± SEM) 407.9 ± 70.7 457.8 ± 40.8 404.2 ± 60.9 441 ± 33.7 0.76
a
𝑃 value obtained with analysis of covariance using log transformed data and corrected for age and gender.
4. Discussion
At best of our knowledge the present is the first case-control
study performed in Caucasians and aimed at addressing the
contribution of the RFC-1 80G>A polymorphism to late-
onset AD risk. The study revealed no significant difference
in RFC-1 allele or genotype frequencies between late-onset
AD patients and healthymatched controls, both results being
very similar between the two groups (Table 2). In addition, no
significant effect of the studied polymorphism on circulating
levels of folate, vitamin B12, or t-hcy was observed (Table 3).
In their original report, Bi and coworkers included
275 late-onset AD patients and 271 age-matched controls
observing an additive effect for the G allele and odds ratios
(ORs) ranging from 1.4 to 1.6 for genotype comparisons. The
present study had enough power to detect similar ORs under
an additive genetic model or at least to detect some trends
toward an association. However, both allele and genotype
frequencies were closely similar between AD patients and
controls; the ORs for genotype comparison were close to 1.0
and the respective 𝑃 values did not even suggest trends for
association. Therefore, rs1051266 is unlikely to represent an
independent risk factor for sporadic AD in our population,
at least with a similar effect size as previously reported in
Han Chinese individuals [15]. Furthermore, present results
are in agreement with those of Mansoori and coworkers who
screened 80 AD patients, 50 patients with vascular dementia,
and 120 healthy control subjects from India, observing an
increased risk of dementia in subjects with low serum
folate values but no association of rs1051266 with circulating
folate levels and risk of AD or vascular dementia [21]. In
addition, Białecka and coworkers [22] screened 248 PD
individuals and 254matched controls fromPoland, searching
for correlation between rs1051266 and risk of dementia in
Parkinson’s disease. The authors observed that both age and
plasma hcy levels were risk factors for dementia in PD but
failed to find association of the RFC-1 80G>A polymorphism
with cognitive decline or plasma hcy levels [22]. Similarly,
Kumudini and coworkers [27] recently screened a cohort of
151 Indian PD patients and 416 healthy controls, observing
increased plasma hcy levels in PD patients than in controls
but no association of the RFC-1 80G>A polymorphism with
either PD risk or plasma hcy levels [27].
Taken overall, both the present and the four previous
studies performed in individuals with different forms of
dementia or neurodegeneration [15, 21, 22, 27] failed to
find association of the RFC-1 80G>A polymorphism with
circulating folate, hcy, or vitamin B12 levels, and only one
study [15] suggests association with dementia of Alzheimer’s
type.
Several factors could account for the above conflicting
results, including differences in allele frequency, dietary
habits, environmental and geographic factors, and the pres-
ence or absence of other genetic variants. For example, the
frequency of the alleles generated by the RFC-1 80G>A
polymorphism varies among different populations, with the
RFC-1 G allele often reported to be the major allele in certain
populations [18, 21, 25] and the minor allele in others [15, 28].
Dietary regimens rich in folate, such as the Mediterranean
diet, could mask the effect of certain polymorphisms, as
it happens for the MTHFR 677C>T one, the most studied
polymorphism of the folate pathway, which is associated with
increased risk of sporadic AD inAsians but not in Caucasians
[16]. It was also suggested that geographic factors, such as
the latitude, could interfere with ultraviolet B solar radiation
and promote, in less pigmented skins, intravascular folate
photolysis, thereby affecting circulating folate levels and folate
metabolism [29]. In this regard, a recent literature meta-
analysis reported a significant effect of the MTHFR 677C>T
polymorphism on pregnancy outcome only in subtropical
regions [29], and it is also of interest that the RFC-1 80G>A
polymorphism was associated with increased chromosome
damage in blood cells of healthy Australian individuals but
not in those of healthy Italian ones [30, 31]. Moreover, the
presence/absence of other polymorphisms of the pathway
could mask or potentiate the effect of a single one [26].
Altogether those factors can account for a different weight
of each genetic polymorphism on a given disease among
different populations, and also the APOE 𝜀4 variant, which
is the most known and replicated risk factor for sporadic
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AD, seems to confer different relative risks in different ethnic
groups [32].
Interestingly, we observed reduced serum folate levels in
AD patients with respect to controls, and this is in agreement
with several recent reports suggesting that reduced serum
folate levels are a valuable biomarker of AD in aged indi-
viduals and might be linked to increased atrophy of both
cortical and subcortical regions [21, 26, 33, 34]. However, as
discussed above, neither the present nor the previous studies
observed association of the RFC-1 80G>A polymorphism
with serum folate levels in individuals affected by different
forms of dementia or neurodegeneration [15, 21, 22, 27].
A limitation of the present study is that patients were
selected retrospectively among prevalent AD cases followed
up at our neurological clinics.The cognitive decline leading to
AD usually starts several years before the onset of dementia,
a condition which is referred to asmild cognitive impairment
(MCI) [35]. The analysis of individuals with MCI would
help to better clarify factors linked to the earliest phases of
the disease than the analysis of late onset AD cases [35],
and a similar study is highly desired in order to clarify
the contribution of both present and other polymorphisms
of the folate metabolic pathway to the earliest phases of
the neurodegenerative process leading to AD. MCI patients
should, however, be followed up over a period of time in
order to discriminate those that will develop dementia of AD
type from other forms of dementia. Indeed, the question of
whether or not impairments of the folate metabolic pathway
are cause or consequence of the neurodegenerative process in
AD is still open in the literature [8–10]. In order to minimize
factors, such as polymedications, that could interfere with
the measured values of folate, hcy, and vitamin B12, we
have not included in the present study patients or controls
taking drugs or vitamin supplements known to alter those
metabolites. In addition, in order to minimize the effect of
geographic factors, both cases and controls had the same
geographical origin and were residents of Pisa, Florence, and
neighbouring areas at the time of enrolment for the study.
Another limitation that we should acknowledge is that we
had no opportunity to measure folate, hcy, and vitamin B12
in the whole cohort of subjects but only in a subgroup of
them. As a consequence, data shown in Table 3 should be
takenwith caution, and replication in a larger cohort of Italian
elderly subjects is warranted prior to exclude a role for the
studied polymorphism on circulating folate, hcy, and vitamin
B12 levels. In this regard, a large similar study, performed
in over 1.000 elderly English subjects (mean age 77.9 years),
revealed no association of the RFC-1 80G>A polymorphism
with circulating folate or hcy levels [36], supporting present
andprevious observations in patientswith neurodegenerative
diseases and their matched controls [15, 21, 22, 27].
In conclusion, the present pilot study does not support a
role for the RFC-1 80G>Apolymorphism as independent risk
factor for sporadic AD in Italian Caucasians. Despite that the
group of patients and controls was relatively small, both allele
and genotype frequencies results were so similar between AD
and control samples that not even a trend for association
was detected. Furthermore, no functional contribution of the
studied polymorphism on circulating levels of folate, t-hcy,
and vitamin B12 was observed. However, a large prospective
study is warranted to confirm the results of the present pilot
study and exclude a role for this polymorphism in the onset
of dementia of Alzheimer’s type in Italian Caucasians.
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